Clinical Trial Update: Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating BCMA-PD1-CART cells for safety and efficacy in relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-PD1-CART cells

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN